See the published version of this preprint at BMC Neurology.
This is a preprint, a preliminary version of a manuscript that has not completed peer review at a journal. Research Square does not conduct peer review prior to posting preprints. The posting of a preprint on this server should not be interpreted as an endorsement of its validity or suitability for dissemination as established information or for guiding clinical practice.
Learn more about In Review
Research Article
Jeong-Ho Hong
Keimyung University Dongsan Medical Center
Corresponding Author
License:
This work is licensed under a CC BY 4.0 License. Read Full License
Background: Carotid stenosis is a known risk factor for ischemic stroke, and carotid artery stenting is an effective preventive procedure. However, the stroke risk reduction for asymptomatic patients is small. Therefore, it is important to reduce the risk of complications, particularly in asymptomatic carotid stenosis. Statins are known to reduce the overall risk of periprocedural complications, although there is a lack of data focusing on asymptomatic patients. We aimed to investigate whether different doses of statin pretreatment can reduce periprocedural complications of carotid artery stenting in patients with asymptomatic carotid artery stenosis.
Methods: Between July 2003 and June 2013, 276 consecutive patients received carotid artery stenting (CAS) for asymptomatic carotid stenosis. Periprocedural complications included the outcome of stroke, myocardial infarction, or death within 30 days of CAS. Statin pretreatment was categorized as no-statin (n=87, 31.5%), standard-dose (<40 mg, n=139, 50.4%), and high-dose statin (≥40 mg, n=50, 18.1%) according to the atorvastatin equivalent dose. Cochran-Armitage (CA) trend test was performed for periprocedural complications to investigate the association with statin dose.
Results: The overall periprocedural complication rate was 3.3%. There was no significant difference in the risk of periprocedural complications between the three groups (no statin: n=3 [3.4%]; standard-dose: n=4 [2.9%]; high-dose n=2 [4.0%] p = 0.923). CA trend test did not demonstrate a trend in the proportion of periprocedural complications across increasing statin equivalent dose (p = 0.919).
Conclusions: Statin pretreatment before CAS showed neither absolute nor dose-dependent effects against periprocedural complications in asymptomatic patients with CAS.
Keywords
carotid stenosis, stents, complications, statin
This is a list of supplementary files associated with this preprint. Click to download.
- SupplementaryMaterial.docx
Supplementary Table I. Summary of statin drug and dose use before carotid artery stenting. Supplementary Table II. Periprocedural complications within 30 days of stenting for asymptomatic carotid artery stenosis
Loading...
Badges
Prescreen
This manuscript passed our Prescreen assessment
Complete author information
Appropriate declaration statements
Potential risks to human health
Prescreen
Peer Review Timeline
CURRENT STATUS: Published
View the published article at BMC Neurology.
Version 1
Posted 17 Dec, 2020
No community comments so far
Editorial decision: Major revision
On 18 Jan, 2021
Reviews received
Received 02 Jan, 2021
Reviewers agreed
On 21 Dec, 2020
Reviewers invited
Invitations sent on 21 Dec, 2020
Editor assigned
On 16 Dec, 2020
Editor invited
On 15 Dec, 2020
Submission checks complete
On 15 Dec, 2020
First submitted
On 28 Nov, 2020
Metrics
Comments: 0
PDF Downloads: ...
HTML Views: ...
Learn more about our company.
See the published version of this preprint at BMC Neurology.
This is a preprint, a preliminary version of a manuscript that has not completed peer review at a journal. Research Square does not conduct peer review prior to posting preprints. The posting of a preprint on this server should not be interpreted as an endorsement of its validity or suitability for dissemination as established information or for guiding clinical practice.
Learn more about In Review
Research Article
Jeong-Ho Hong
Keimyung University Dongsan Medical Center
Corresponding Author
Badges
Prescreen
This manuscript passed our Prescreen assessment
Complete author information
Appropriate declaration statements
Potential risks to human health
Prescreen
Peer Review Timeline
CURRENT STATUS: Published
View the published article at BMC Neurology.
Version 1
Posted 17 Dec, 2020
No community comments so far
Editorial decision: Major revision
On 18 Jan, 2021
Reviews received
Received 02 Jan, 2021
Reviewers agreed
On 21 Dec, 2020
Reviewers invited
Invitations sent on 21 Dec, 2020
Editor assigned
On 16 Dec, 2020
Editor invited
On 15 Dec, 2020
Submission checks complete
On 15 Dec, 2020
First submitted
On 28 Nov, 2020
Metrics
Comments: 0
PDF Downloads: ...
HTML Views: ...
License:
This work is licensed under a CC BY 4.0 License. Read Full License
View the published article at BMC Neurology.
Background: Carotid stenosis is a known risk factor for ischemic stroke, and carotid artery stenting is an effective preventive procedure. However, the stroke risk reduction for asymptomatic patients is small. Therefore, it is important to reduce the risk of complications, particularly in asymptomatic carotid stenosis. Statins are known to reduce the overall risk of periprocedural complications, although there is a lack of data focusing on asymptomatic patients. We aimed to investigate whether different doses of statin pretreatment can reduce periprocedural complications of carotid artery stenting in patients with asymptomatic carotid artery stenosis.
Methods: Between July 2003 and June 2013, 276 consecutive patients received carotid artery stenting (CAS) for asymptomatic carotid stenosis. Periprocedural complications included the outcome of stroke, myocardial infarction, or death within 30 days of CAS. Statin pretreatment was categorized as no-statin (n=87, 31.5%), standard-dose (<40 mg, n=139, 50.4%), and high-dose statin (≥40 mg, n=50, 18.1%) according to the atorvastatin equivalent dose. Cochran-Armitage (CA) trend test was performed for periprocedural complications to investigate the association with statin dose.
Results: The overall periprocedural complication rate was 3.3%. There was no significant difference in the risk of periprocedural complications between the three groups (no statin: n=3 [3.4%]; standard-dose: n=4 [2.9%]; high-dose n=2 [4.0%] p = 0.923). CA trend test did not demonstrate a trend in the proportion of periprocedural complications across increasing statin equivalent dose (p = 0.919).
Conclusions: Statin pretreatment before CAS showed neither absolute nor dose-dependent effects against periprocedural complications in asymptomatic patients with CAS.
This is a list of supplementary files associated with this preprint. Click to download.
- SupplementaryMaterial.docx
Supplementary Table I. Summary of statin drug and dose use before carotid artery stenting. Supplementary Table II. Periprocedural complications within 30 days of stenting for asymptomatic carotid artery stenosis
Loading...